Yingjie Yang

Guiyang, 550001, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 10 publications

A phase I dose-escalation study of Lobaplatin combined with paclitaxel in platinum-sensitive recurrent ovarian epithelial carcinoma: preliminary safety and tolerability supporting clinical trial dosing.

A phase I dose-escalation study of Lobaplatin combined with paclitaxel in platinum-sensitive recurrent ovarian epithelial carcinoma: preliminary safety and tolerability supporting clinical trial dosing.

Journal: Gynecologic oncology reports

Published: January 10, 2026

Fuzuloparib with or without apatinib as maintenance therapy in newly diagnosed, advanced ovarian cancer (FZOCUS-1): A multicenter, randomized, double-blind, placebo-controlled phase 3 trial.

Fuzuloparib with or without apatinib as maintenance therapy in newly diagnosed, advanced ovarian cancer (FZOCUS-1): A multicenter, randomized, double-blind, placebo-controlled phase 3 trial.

Journal: CA: a cancer journal for clinicians

Published: September 15, 2025

A multicenter, prospective, non-interventional drug intensive monitoring study of olaparib in a large real-world Chinese patient cohort with ovarian cancer (DIM-OC).

A multicenter, prospective, non-interventional drug intensive monitoring study of olaparib in a large real-world Chinese patient cohort with ovarian cancer (DIM-OC).

Journal: Journal of ovarian research

Published: August 12, 2025

RECQL4 as a novel drug target against ovarian cancer.

RECQL4 as a novel drug target against ovarian cancer.

Journal: Biochemical pharmacology

Published: June 10, 2025

Treatment With Niraparib Maintenance Therapy in Patients With Newly Diagnosed Advanced Ovarian Cancer: A Phase 3 Randomized Clinical Trial.

Treatment With Niraparib Maintenance Therapy in Patients With Newly Diagnosed Advanced Ovarian Cancer: A Phase 3 Randomized Clinical Trial.

Journal: JAMA oncology

Published: July 13, 2023

A risk prediction model mediated by genes of APOD/APOC1/SQLE associates with prognosis in cervical cancer.

A risk prediction model mediated by genes of APOD/APOC1/SQLE associates with prognosis in cervical cancer.

Journal: BMC women's health

Published: July 04, 2022

Clinicopathological characteristics and survival outcomes in human papillomavirus independent cervical cancer: a propensity score matched analysis.

Clinicopathological characteristics and survival outcomes in human papillomavirus independent cervical cancer: a propensity score matched analysis.

Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

Published: March 25, 2022

Effects of m6A RNA methylation regulators on endometrial cancer.

Effects of m6A RNA methylation regulators on endometrial cancer.

Journal: Journal of clinical laboratory analysis

Published: June 03, 2021

Real-world Experience of Olaparib Treatment in Patients with Ovarian Cancer: A Chinese Multicenter Study.

Real-world Experience of Olaparib Treatment in Patients with Ovarian Cancer: A Chinese Multicenter Study.

Journal: Molecular cancer therapeutics

Published: December 22, 2020

Distribution of human papilloma virus type 16 E6/E7 gene mutation in cervical precancer or cancer: A case control study in Guizhou Province, China.

Distribution of human papilloma virus type 16 E6/E7 gene mutation in cervical precancer or cancer: A case control study in Guizhou Province, China.

Journal: Journal of medical virology

Published: July 17, 2015

Showing 1-10 of 10

Last Updated: 09/26/2026